文献速递技术与安全PETCT

接受多次18F-FDG PET/CT检查的患者:检查频率、剂量与疾病分类评估

Patients undergoing multiple 18F-FDG PET/CT exams: Assessment of frequency, dose and disease classification.
PubMed 文献 · Br J Radiol · 2022-05-05

该回顾性研究在三级医院分析两年内接受≥2次18F-FDG PET/CT的患者,共10,714次检查、6,831例患者,人均1.6次,20.9%患者单年内≥2次,中位剂量25.1 mSv,12-13%患者累积有效剂量≥100 mSv,主要病种为黑色素瘤、非霍奇金淋巴瘤、胃肠道癌、乳腺癌和霍奇金淋巴瘤。

要点

  • 单年内20.9%患者接受≥2次18F-FDG PET/CT,两年内约四分之一患者多次检查。
  • 单次检查中位剂量25.1 mSv,最高达中位值的1.7至2.9倍。
  • 12-13%患者累积有效剂量≥100 mSv,包括预期寿命较长者。

核心结论

  • 相当数量患者接受≥2次18F-FDG PET/CT,八分之一患者累积剂量≥100 mSv,其中包括预期寿命较长者。

研究设计与样本

  • 回顾性研究,在三级医院连续两年识别单年内接受≥2次18F-FDG PET/CT的患者,共6,831例患者、10,714次检查;CT辐射剂量采用剂量长度乘积和性别特异性转换因子计算,原发恶性肿瘤从电子病历获取。

诊断标准与关键数值

  • 单次18F-FDG PET/CT检查中位剂量25.1 mSv,最高值为中位值的1.7至2.9倍。
  • 12-13%患者累积有效剂量≥100 mSv。
  • 两年合计累积剂量第25、50、75百分位及均值均超过100 mSv,第25百分位为109 mSv。
  • 多次系列18F-FDG PET/CT的原发恶性肿瘤按频率递减依次为黑色素瘤、非霍奇金淋巴瘤、胃肠道癌、乳腺癌和霍奇金淋巴瘤。

临床应用与阅片要点

  • 单年内20.9%患者接受≥2次18F-FDG PET/CT,两年内约四分之一患者多次检查。
  • 八分之一患者累积有效剂量≥100 mSv,包括预期寿命较长者。
  • 系列检查最常见病种依次为黑色素瘤、非霍奇金淋巴瘤、胃肠道癌、乳腺癌和霍奇金淋巴瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To analyse the frequency, demographics, primary disease and cumulative effective dose of patients undergoing two or more 18F-FDG PET/CT examinations in a year.

METHODS: In a retrospective study performed at a tertiary-care hospital, patients who underwent ≥2 18F-FDG PET/CT scans in a calendar year were identified for two consecutive years. The CT radiation dose was calculated using dose-length-product and sex-specific conversion factors. The primary malignancy of patients was retrieved from electronic medical records.

RESULTS: 10,714 18F-FDG PET/CT exams were performed for 6,831 unique patients in 2 years, yielding an average of 1.6 exams per patient. The maximum number of 18F-FDG PET/CT examinations any patient underwent in a single year was seven. 20.9% patients had ≥2 18F-FDG PET/CT exams in any single year. Thirty nine percent patients in the cohort were below 60 years age. The median dose for 18F-FDG PET/CT examination was 25.1 mSv and maximum value reaching 1.7 to 2.9 times the median value. Cumulative effective dose (CED) was≥100 mSv in 12-13% of the patients. The cumulative dose for both years combined demonstrated the 25th percentile, 50th percentile and 75th percentile as well as the mean to be over 100 mSv, with the 25th percentile being 109 mSv. The dominant primary malignancies contributing to serial 18F-FDG PET/CTs in decreasing frequency were melanoma, non-Hodgkin's lymphoma (NHL), gastrointestinal cancer, breast cancer and Hodgkin's lymphoma.

CONCLUSIONS: A sizeable number of patients undergo≥2 18F-FDG PET/CT exams with one out of every eight patients receiving cumulative dose≥100 mSv and that includes patients with long-life expectancy.

ADVANCES IN KNOWLEDGE: The study found that one of five patients had≥2 18F-FDG PET/CT exams in a calendar year, one of four patients in two years and one of eight patients received cumulative dose≥100 mSv. Top malignancies associated with serial imaging in decreasing order of frequency included melanoma, non-Hodgkin's lymphoma (NHL), gastrointestinal cancer, breast cancer and Hodgkin's lymphoma.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Indrakanti, Li, Rehani, et al. Patients undergoing multiple 18F-FDG PET/CT exams: Assessment of frequency, dose and disease classification. Br J Radiol. 2022. PMID: 35348374. doi:10.1259/bjr.20211225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。